SMR | Conference

Adil Daud, MD, spoke about the emergence of next-generation sequencing and the importance of testing patients with melanoma for BRAF mutations.

Jeffrey Weber, MD, PhD, discusses the unmet needs professionals take into consideration when deciding treatment options for patients with melanoma.

Data from the COMBI-AD Trial evaluating dabrafenib and trametinib to treat melanoma was analyzed by Hussein Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center.